Azora Therapeutics, Inc.
AZR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.26M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $13.26 Million |
|---|---|
| Enterprise Value | $-15,451,255.00 |
| Earnings per Share | $- |
| Beta | 1.5 |
| Outstanding Shares | - |
Return
| Return on Equity | 150.61% |
|---|---|
| Return on Assets | -198.70% |
| Return on Invested Capital | -240.64% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.27 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-1.03
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.17
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Adial Pharmaceuticals Inc
2,018 employees
CEO: Cary J. Claiborne
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.